Illumina, Inc. ILMN today announced GRAIL, a new company formed
to enable cancer screening from a simple blood test. Powered by Illumina
sequencing technology, GRAIL will develop a pan-cancer screening test by
directly measuring circulating nucleic acids in blood.
Detecting cancer at the earliest stages dramatically increases long-term
survival, hence the successful development of a pan-cancer screening
test for asymptomatic individuals would make the first major dent in
global cancer mortality.
GRAIL's unique structure enables it to take on this grand challenge.
GRAIL has been formed as a separate company, majority owned by Illumina.
GRAIL is initially funded by over $100 million in Series A financing
from Illumina
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in